Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment.

ABSTRACT:

Background

Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation.

Aim

The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.

Methods

We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolv

SUBMITTER: Poola S 

PROVIDER: S-EPMC12904191 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature